-
2024-514261-19-00
9
2025-03-24
Locally advanced, unresectable or metastatic cholangiocarcinoma with a
-
2024-515445-42-00
5
2025-03-24
Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
-
2022-500574-34-00
4
2025-03-21
Waldenström’s Macroglobulinemia
-
2024-513285-19-00
1
2025-03-14
Pancreatic Ductal Adeno Carcinoma
-
2024-515732-68-00
1
2025-03-07
Huntington’s disease
-
2023-510292-65-00
5
2025-02-25
chronic graft-versus-host disease
-
2023-509748-89-00
7
2025-02-19
Facioscapulohumeral muscular dystrophy (FSHD)
-
2022-502352-31-00
5
2025-02-10
Colorectal Cancer (CRC)
-
2024-511037-35-00
4
2025-01-31
Cyclosporine A is a well known medication and is used to prevent rejec
-
2023-505320-54-00
4
2025-01-30
Multiple System Atrophy
-
2023-508234-34-00
4
2025-01-27
Crohn's disease
-
2023-510323-30-00
5
2025-01-24
First-line treatment of recurrent or metastatic PD-L1+ head and neck s
-
2024-513852-13-00
5
2025-01-20
KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Col
-
2024-514129-43-00
4
2025-01-15
Metastatic pancreatic ductal adenocarcinoma
-
2023-508813-18-00
4
2024-12-18
Refractory Focal Onset Epilepsy
-
2024-511099-34-00
1
2024-12-12
B-Cell Malignancies
-
2022-500455-23-00
5
2024-12-11
Candidemia
-
2023-510150-17-00
4
2024-12-11
Active, refractory systemic lupus erythematosus (SLE), and active, re
-
2023-510380-34-00
4
2024-12-10
Diffuse cutaneous systemic sclerosis (dcSSc)
-
2024-513860-25-00
9
2024-12-10
Ovarian Neoplasms
-
2023-508960-31-00
5
2024-12-03
Metastatic HER2-positive breast cancer
-
2024-512279-10-00
5
2024-11-25
Triple Negative Breast Cancer
-
2024-513009-30-00
4
2024-11-21
Moderate to Severe Crohn’s Disease
-
2024-514917-36-00
5
2024-11-21
Patients with High Risk Neuroblastoma